FIELD: medicine.
SUBSTANCE: antibody to the repelling signal molecule a (RGMa) is proposed. Also a pharmaceutical composition comprising the said antibody and a method for treatment, prevention, modulation or decrease of the severity of a disease or disorder associated with neurites degeneration is proposed.
EFFECT: invention can find further application in the therapy of neurodegenerative diseases such as multiple sclerosis.
31 cl, 20 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| ANTIBODY TO IL-4Rα AND APPLICATION THEREOF | 2018 |
|
RU2758092C1 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
| ANTIBODIES TO MST1R AND THEIR APPLICATION | 2010 |
|
RU2534890C2 |
| MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY | 2014 |
|
RU2709741C2 |
| ANTIBODIES TO GLUCAGON RECEPTOR AND THEREOF APPLICATION | 2009 |
|
RU2562110C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
